ArticleAdvances in urology2011
Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study).
Article in Advances in urology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?International urogynecology journal · 2021Pooled it
- Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.International urology and nephrology · 2015Pooled it
- Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors.Cancer medicine · 2021Trial
- Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial.International journal of chronic obstructive pulmonary disease · 2019Trial
- Effectiveness of Solifenacin for Managing of Bladder Spasms in Patients With Urethroplasty.American journal of men's health · 2017Trial
- Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.The Cochrane database of systematic reviews · 2023Review
- Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis.Drugs in context · 2022Article
- Impact of a direct-to-consumer information campaign on prescription patterns for overactive bladder.BMC health services research · 2018Article
- Effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury.Spinal cord · 2017Article
- Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?International urogynecology journal · 2015Review
- A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.Journal of clinical and diagnostic research : JCDR · 2015Article
- Imidafenacin on bladder and cognitive function in neurologic OAB patients.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2013Article
- Experience with imidafenacin in the management of overactive bladder disorder.Therapeutic advances in urology · 2013Article
- Long-term safety, efficacy, and tolerability of imidafenacin in the treatment of overactive bladder: a review of the Japanese literature.Patient preference and adherence · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives. Overactive bladder (OAB) is a chronic disease, but comparative trials of anticholinergics, which are commonly used for treatment of OAB, have generally been performed for up to 12 weeks only. There is no comparative study of a long-term intervention. Methods. We conducted a 52-week prospective randomized comparative study to evaluate the efficacy and tolerability of two anticholinergics. Results. Forty-one Japanese patients with untreated OAB were randomly assigned to imidafenacin and solifenacin groups. There was no difference in OABSS and KHQ scores between the two groups, but the severity and incidence of adverse events caused by the anticholinergics showed increased differences between the groups with time. The severity of dry mouth and the incidence of constipation were significantly lower in the imidafenacin group (P = 0.0092 and P = 0.0013, resp.). Conclusions. This study is the first long-term trial to show differences in the properties of anticholinergics that were not detected in short-term studies. Since OAB is a chronic disease, we conclude that imidafenacin is preferable to solifenacin from a perspective of safety.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.